Pharma

CinFina Pharma Announces FDA Clearance of Investigational New Drug Application and First Participants Dosed in Phase 1 Trial of CIN-110 for the Treatment of Obesity

Retrieved on: 
Tuesday, March 26, 2024
Research, FDA, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Human, PYY, Obesity, Neuropeptide, Appetite, Patient, Weight loss, Trial of the century, IND, Nausea, PYY3-36, Safety, Pharmacokinetics, Therapy, Vomiting, Y2R, Pharma, Food, DSM-IV codes, Pharmaceutical industry

With the commencement of the trial, CinFina also announced the first cohort of participants has been dosed.

Key Points: 
  • With the commencement of the trial, CinFina also announced the first cohort of participants has been dosed.
  • The trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of CIN-110 in a randomized, double-blind, placebo-controlled, single ascending dose study in otherwise healthy subjects with obesity.
  • PYY3-36 is an endogenous hormone secreted in the gut, which activates the neuropeptide Y2 receptor (Y2R) to reduce appetite and food intake.
  • “The preclinical program of CIN-110 underscores the potential for PYY to be a differentiated approach to treat obesity.

Global Clinical Trials Connect Conference 2024: London, United Kingdom - May 28-29, 2024 - Registration Now Open - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 26, 2024
Health, Health Technology, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Diagnosis, ChromeOS, External, Learning, Partnership, Global health, Bioethics, Pleasure, Pharma

The "Global Clinical Trials Connect 2024" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Clinical Trials Connect 2024" conference has been added to ResearchAndMarkets.com's offering.
  • The Global Clinical Trials Connect 2024 will provide a platform to discuss on the futuristic advancements in clinical trials and clinical research.
  • This multidisciplinary program involves broad participation of people from clinical trials community from around the globe who are focused on learning more about clinical research, clinical trials planning and management.
  • It gives us a great pleasure in welcoming you to the Global Clinical Trials Connect 2024.

Horus Pharma Renews Its Partnership With Plastic Bank

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Manufacturing, Other Health, Health, Environmental Issues, Environmental Health, Optical, Recycling, Other Manufacturing, Environment, Chemicals, Plastics, Partnership, Education, Eye, Multimedia, Plastic Bank, Social, Mediterranean Basin, Pharma, Ophthalmology

Horus Pharma, an independent French laboratory specialised in ophthalmology known for its expertise in developing preservative-free products designed to facilitate eye and eyelid health, has extended its successful collaboration with Plastic Bank, a global organisation focused on reducing and recycling plastic waste and championing a circular economy.

Key Points: 
  • Horus Pharma, an independent French laboratory specialised in ophthalmology known for its expertise in developing preservative-free products designed to facilitate eye and eyelid health, has extended its successful collaboration with Plastic Bank, a global organisation focused on reducing and recycling plastic waste and championing a circular economy.
  • View the full release here: https://www.businesswire.com/news/home/20240325128322/en/
    In late 2022, Horus Pharma made a pledge alongside Plastic Bank to recycle the quantity of plastic used in the packaging for 10 of its products.
  • Horus Pharma is thus offsetting 65% of the plastic volumes it puts on the market, with 400 metric tons of plastic set to be recycled between year-end 2022 and year-end 2025.
  • Nicolas Claret, Horus Pharma’s International Director, commented: “In the pharma industry, plastic often has to be used to meet regulatory standards and comply with globally recognised good manufacturing practices.

Curaleaf International Comments As German Federal Cannabis Law Passes Without Delay

Retrieved on: 
Friday, March 22, 2024
Science, Legal, Research, Natural Resources, Alternative Medicine, Health, Professional Services, Cannabis, Pillar, Bundestag, Growth, Environment, Cannabis Act, Patient, Sale, Prescription, Terra Verde, Insurance, Cabinet of Germany, Pharmacy, Curaleaf, Pharma, Legislation, Drug

Today, it has been announced that the German Federal Government's cannabis law, also known as Pillar 1, has successfully progressed without delay.

Key Points: 
  • Today, it has been announced that the German Federal Government's cannabis law, also known as Pillar 1, has successfully progressed without delay.
  • Juan Martinez, Head of Curaleaf International, a leading cannabis company in Europe, commented:
    "The successful passage of the Cannabis Act represents a significant milestone in our journey towards destigmatisation and decriminalisation of cannabis for both patients and consumers.
  • As a company deeply invested in the European cannabis landscape, we are excited about the opportunities this legislation brings.
  • Our full seed-to-sale process allows us first mover advantage to meet the anticipated demand from a thriving, regulated, and safe cannabis industry.

IFF Announces Sale of its Pharma Solutions Business to Roquette

Retrieved on: 
Tuesday, March 19, 2024
Pharmaceutical, Health, Specialty, Chemicals, Plastics, Food, Beverage, Cosmetics, Manufacturing, Retail, Slate, Growth, Science, Partnership, Patient, Research, Sale, Excipient, Creativity, Pharma, Fine chemical

IFF (NYSE: IFF) today announced that it has entered into a definitive agreement to sell its Pharma Solutions business unit to French leader of plant-based ingredients Roquette for an enterprise value of up to $2.85 billion, which represents an enterprise value to EBITDA multiple of approximately 13x.

Key Points: 
  • IFF (NYSE: IFF) today announced that it has entered into a definitive agreement to sell its Pharma Solutions business unit to French leader of plant-based ingredients Roquette for an enterprise value of up to $2.85 billion, which represents an enterprise value to EBITDA multiple of approximately 13x.
  • IFF’s Pharma Solutions business is a well-established developer and manufacturer of pharmaceutical excipients and includes its Global Specialty Solutions business supporting industrial and methyl cellulosic food applications.
  • The Pharma Solutions business being sold to Roquette is primarily made up of businesses within IFF’s existing Pharma Solutions division, with some adjustments to the perimeter of the transaction designed to align customers, businesses and the manufacturing footprint.
  • “We are pleased to reach an agreement with Roquette that will support Pharma Solutions’ next chapter of growth as a trusted partner for the pharmaceutical industry,” said IFF CEO Erik Fyrwald.

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Appoints Renowned Oculoplastic Surgeon, John P. Fezza, MD to Its Medical Advisory Board

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Surgery, Health, Pharmaceutical, Optical, MAB, Drainage, Alcon, Private practice, Telecanthus, Patient, Bausch & Lomb, MBA, Ophthalmology, Optometry, FDA, Pharma, Pharmaceutical industry

Dr. Fezza joins the MAB as Nordic Pharma prepares to launch a novel therapy for Dry Eye Disease, LACRIFILL® Canalicular Gel.

Key Points: 
  • Dr. Fezza joins the MAB as Nordic Pharma prepares to launch a novel therapy for Dry Eye Disease, LACRIFILL® Canalicular Gel.
  • The FDA-cleared, cross-linked hyaluronic acid derivative LACRIFILL is intended to temporarily block tear drainage by the occlusion of the canalicular system.
  • “The entire U.S. Medical Advisory Board of Nordic Pharma is honored and delighted to welcome John Fezza, MD, a world class oculoplastic surgeon to our MAB,” said Eric Donnenfeld, MD, MAB Chair.
  • Nordic Pharma is committed to engaging ophthalmologists and optometrists in the early launch stages of LACRIFILL Canalicular Gel.

Bormioli Pharma Expands Capacity and Infrastructure for North American Market; Achieves 47% Sales Growth in the Region During 2023

Retrieved on: 
Tuesday, March 12, 2024
Medical Supplies, Biotechnology, Manufacturing, Professional Services, Health, Pharmaceutical, Environmental, Social and Governance (ESG), Medical Devices, Packaging, Environment, Sustainability, Growth, Partnership, DCAT, ESG, Sterilization, Glass, Safety, Multimedia, FDA, Pharma, Fine chemical

Bormioli Pharma, a leading international manufacturer of pharmaceutical packaging and medical devices, today announced a significant increase of 47% in its North American sales for 2023.

Key Points: 
  • Bormioli Pharma, a leading international manufacturer of pharmaceutical packaging and medical devices, today announced a significant increase of 47% in its North American sales for 2023.
  • This notable growth is a direct result of the company's rapidly evolving infrastructure and expanded capacity, tailored to meet the unique demands of the North American pharmaceutical market, including an increased need for pharmaceutical glass vials.
  • View the full release here: https://www.businesswire.com/news/home/20240312445175/en/
    Bormioli Pharma's expanded capacity and infrastructure enables the company to provide dedicated product offerings compatible with North American regional standards.
  • Furthermore, Bormioli Pharma recently partnered with leading Canadian clean technology company , Loop Industries, to use 100% recycled virgin-quality Loop™ PET resin for developing a novel pharmaceutical packaging bottle.

IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline

Retrieved on: 
Tuesday, March 12, 2024
Other Health, Technology, Pharmaceutical, Mental Health, Infectious Diseases, Neurology, Artificial Intelligence, Clinical Trials, Other Technology, Science, Biotechnology, Alternative Medicine, Other Science, Health, Research, NCI, Agitation, Patient, Committee, National Cancer Institute, Virology, University, Quality of life, NIH, House, Myenteric plexus, Pancreatic Cancer Action Network, University of Maryland, Baltimore, Fetal alcohol spectrum disorder, IGC, IHV, Pharma, Jan Vansina, Bangladesh Technical Education Board, Therapy, Senate, Dementia, Public affairs, Pharmaceutical industry

IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) today announced that it has appointed Terry Lierman as an independent director to its board of directors.

Key Points: 
  • IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) today announced that it has appointed Terry Lierman as an independent director to its board of directors.
  • Terry founded the Children’s Research Institute, one of America's top children’s research programs, the Pancreatic Cancer Action Network (PanCAN), and the National Organization on Fetal Alcohol Syndrome (NOFAS).
  • Ram Mukunda, CEO of IGC Pharma, commented, “With his track record of execution and extensive experience in health care, Mr. Lierman will undoubtedly bring invaluable insights and strategic guidance to IGC Pharma.
  • I look forward to collaborating with the talented team at IGC Pharma to drive forward the mission of bringing transformative therapies to patients in need.”

Vi Announces Groundbreaking Reports on AI's Transformative Impact in Healthcare, Pharma, and Wellness Sectors

Retrieved on: 
Tuesday, April 2, 2024
Organization, Acquisition, AI, LTV, Pharma, Customer, CPA, Medical device

These comprehensive analyses provide an in-depth look at the transformative role of AI across the healthcare, pharma, and wellness sectors, informed by the latest data and advancements in the field.

Key Points: 
  • These comprehensive analyses provide an in-depth look at the transformative role of AI across the healthcare, pharma, and wellness sectors, informed by the latest data and advancements in the field.
  • This critical juncture highlights the significant potential for AI to revolutionize healthcare and wellness through enhancing diagnostic accuracy, streamlining administrative operations, and personalizing patient care.
  • AI shows an enhanced capability to significantly reduce Customer Acquisition Costs (CPA) and increase the Lifetime Value (LTV) of members across the health and wellness sectors.
  • Both reports aim to detail the transformative effects of AI across the healthcare, pharma, and wellness sectors and address the challenges of its broader adoption.

BCC Research Reveals Top Ten Suppliers of Synthetic Biology Technology in 2024

Retrieved on: 
Tuesday, April 2, 2024
Research, Automation, Health, Edit, Enzyme, Growth, Commercialization, Top Ten, Agriculture, Drug discovery, Synthetic biology, Livestock, DNA, Health care, Milk, Food safety, Biofuel, Synthetic, CRISPR, Pharma, Therapy, BCC, Vaccine, Cas9, Food industry

BOSTON, April 2, 2024 /PRNewswire/ -- According to the latest BCC Research study, the demand for Top Ten Suppliers of Synthetic Biology Technology is estimated to increase from $35.5 billion in 2023 to $59.2 billion by the end of 2028, at a compound annual growth rate (CAGR) of 10.8% during the forecast period of 2023-2028.

Key Points: 
  • With growing interest and investment from countries worldwide, synthetic biology promises sustainable solutions and transformative applications across industries.
  • Furthermore, it provides forecasts for 2028, allowing stakeholders to anticipate future trends and opportunities in the synthetic biology sector.
  • Growth in Synthetic Biology Foundries: Synthetic biology foundries serve as collaborative hubs for research and development, providing access to shared resources, expertise, and standardized biological parts.
  • Increasing Research and Development Investment by Pharma Companies: Pharmaceutical companies are increasingly recognizing the potential of synthetic biology and investing in research and development efforts.